Allergy Skin Testing

LCD Information Document Information Source LCD ID N/A LCD ID L33417 Original ICD-9 LCD ID Not Applicable LCD Title Allergy Skin Testing Proposed LCD in Comment Period N/A Source Proposed LCD DL33417 Opens in a new window Original Effective Date For services performed on or after 10/01/2015 Revision Effective Date For services performed on or after 04/15/2021 Revision Ending Date N/A Retirement Date N/A Notice Period Start Date 04/13/2017 Notice Period End Date 05/28/2017 CPT codes, descriptions, and other data only are copyright 2025 American Medical Association. All Rights Reserved. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. CPT is a registered trademark of the American Medical Association. Current Dental Terminology © 2025 American Dental Association. All rights reserved. Copyright © 2026, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB‐04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution, or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at ub04@aha.org or 312‐422‐3366. Making copies or utilizing the content of the UB‐04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB‐04 Manual and/or codes and descriptions; and/or making any commercial use of UB‐04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates. Issue Issue Description Issue - Explanation of Change Between Proposed LCD and Final LCD CMS National Coverage Policy Title XVIII of the Social Security Act, §1862(a)(1)(A) allows coverage and payment for only those services that are considered to be reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member.Title XVIII of the Social Security Act, §1862(a)(1)(D) Investigational or ExperimentalTitle XVIII of the Social Security Act, §1862(a)(6) Personal Comfort ItemsTitle XVIII of the Social Security Act, §1862(a)(7) excludes routine physical examinations42 Code of Federal Regulations §410.20 Physicians' ServicesCMS Internet-Only Manual, Pub. 100-02, Medicare Benefit Policy Manual, Chapter 15, §50.2 Determining Self-Administration of Drug or Biological and §50.4.4.1 AntigensCMS Internet-Only Manual, Pub. 100-03, Medicare National Coverage Determinations Manual, Chapter 1, Part 2, §110.9 Antigens Prepared for Sublingual Administration, §110.11 Food Allergy Testing and Treatment, §110.12 Challenge Ingestion Food Testing and §110.13 Cytotoxic Food Tests Coverage Indications, Limitations, and/or Medical Necessity Allergy skin testing is a clinical procedure that is used to evaluate an immunologic response to allergenic material. The need for testing and interpretation of test findings must be correlated with signs and symptoms of possible allergies as determined by a complete history and physical examination of the patient. The number and type of antigens used for testing must be chosen judiciously given the patient’s presentation and the tester’s clinical judgment.Allergy testing is covered when a patient presents with clinically significant allergic history or symptoms that are not controllable by empiric conservative therapy. For Medicare to cover allergy testing, all of the following criteria must be met: Testing must correlate specifically to the patient’s history and physical findings. The test technique and/or allergens tested must have proven efficacy demonstrated through scientifically valid medical studies published in peer-reviewed literature. Allergy testing must be performed on patients whose environment provides the reasonable probability of exposure to the specific antigen tested. Percutaneous testing is the usual preferred method for allergy testing. Medicare covers percutaneous (scratch, prick or puncture) testing when documented IgE-mediated reactions occur to any of the following: Inhalants Foods Hymenoptera (stinging insects) Specific drugs (penicillins and macromolecular agents) In selected patients, intradermal testing for the same antigen may be necessary to test persons whose percutaneous test was negative. For intradermal testing, the clinician should narrow the area of investigation so that the minimal number of skin tests necessary for diagnosis is performed. Medicare covers intradermal (intracutaneous) testing when documented IgE-mediated reactions occur to any of the following: Inhalants Hymenoptera (stinging insects) Specific drugs (penicillins and macromolecular agents) Retesting with the same antigen(s) should rarely be necessary within a 3-year period. Exceptions include young children with negative skin tests, or older children and adults with negative skin tests in the face of persistent symptoms. Routine repetition of skin tests is not indicated (i.e., annually). If under specific circumstances, extensive repeat testing is required within a 3-year period, those circumstances must be clearly documented in the medical record including an explanation as to why the original testing is unacceptable. Percutaneous testing for food allergens is covered for patients with a clinical presentation suggestive of significant IgE mediated food allergy. Such patients will have presented with signs and symptoms of such conditions as angioedema, urticaria or anaphylaxis after ingestion of specific foods. Testing for food allergies in patients who present with significant respiratory symptoms alone may be required in certain instances. The following allergy testing is non-covered by Medicare: Provocative and neutralization testing and neutralization therapy of food allergies (sublingual, intracutaneous and subcutaneous) are excluded from Medicare coverage because available evidence does not show these tests and therapies are effective Qualitative multiallergen screens have insufficient literature demonstrating clear-cut clinical utility and are, therefore, non-covered Late reactions occurring with allergenic extracts are of unclear clinical significance and are, therefore, non-covered Intradermal testing for food allergens Food allergen testing for patients who present with respiratory symptoms other than wheezing and asthma Food allergen testing for patients who present with gastrointestinal symptoms suggestive of food intolerance Skin endpoint testing Allergy testing for antigens for which no clinical efficacy is documented in peer-reviewed literature. Such antigens include but are not limited to the following: Grain mill dust (pollen grains of cereals/related crops are large; they do not become airborne) Tobacco smoke (no component has ever been shown to be a respiratory allergen) Orris root (almost never used in cosmetics these days; test adds nothing to evaluation) Dandelion (non-allergenic; no pollen produced) Marigold (non-allergenic; no airborne pollen produced) Honeysuckle (non-allergenic; non-significant airborne pollen produced) Allergy testing for certain antigens is covered only when performed on patients whose environment provides the reasonable probability of their exposure to antigens tested. Such antigens include, but are not limited to the following: Tobacco leaf for tobacco workers Pyrethrum for florists (non-allergenic; found in some insecticides; cross-reacts strongly with ragweed) Golden rod for florists (pollen not carried by wind) Soybean dust for workers in food processing plants Wool for patients exposed to sheep or unprocessed wool (processed wool is non-allergenic) Summary of Evidence N/A Analysis of Evidence (Rationale for Determination) N/A

Allergy skin testing is a clinical procedure that is used to evaluate an immunologic response to allergenic material. The need for testing and interpretation of test findings must be correlated with signs and symptoms of possible allergies as determined by a complete history and physical examination of the patient. The number and type of antigens used for testing must be chosen judiciously given the patient’s presentation and the tester’s clinical judgment. Allergy testing is covered when a patient presents with clinically significant allergic history or symptoms that are not controllable by empiric conservative therapy. For Medicare to cover allergy testing, all of the following criteria must be met: Testing must correlate specifically to the patient’s history and physical findings. The test technique and/or allergens tested must have proven efficacy demonstrated through scientifically valid medical studies published in peer-reviewed literature. Allergy testing must be performed on patients whose environment provides the reasonable probability of exposure to the specific antigen tested. Percutaneous testing is the usual preferred method for allergy testing. Medicare covers percutaneous (scratch, prick or puncture) testing when documented IgE-mediated reactions occur to any of the following: Inhalants Foods Hymenoptera (stinging insects) Specific drugs (penicillins and macromolecular agents) In selected patients, intradermal testing for the same antigen may be necessary to test persons whose percutaneous test was negative. For intradermal testing, the clinician should narrow the area of investigation so that the minimal number of skin tests necessary for diagnosis is performed. Medicare covers intradermal (intracutaneous) testing when documented IgE-mediated reactions occur to any of the following: Inhalants Hymenoptera (stinging insects) Specific drugs (penicillins and macromolecular agents) Retesting with the same antigen(s) should rarely be necessary within a 3-year period. Exceptions include young children with negative skin tests, or older children and adults with negative skin tests in the face of persistent symptoms. Routine repetition of skin tests is not indicated (i.e., annually). If under specific circumstances, extensive repeat testing is required within a 3-year period, those circumstances must be clearly documented in the medical record including an explanation as to why the original testing is unacceptable. Percutaneous testing for food allergens is covered for patients with a clinical presentation suggestive of significant IgE mediated food allergy. Such patients will have presented with signs and symptoms of such conditions as angioedema, urticaria or anaphylaxis after ingestion of specific foods. Testing for food allergies in patients who present with significant respiratory symptoms alone may be required in certain instances. The following allergy testing is non-covered by Medicare: Provocative and neutralization testing and neutralization therapy of food allergies (sublingual, intracutaneous and subcutaneous) are excluded from Medicare coverage because available evidence does not show these tests and therapies are effective Qualitative multiallergen screens have insufficient literature demonstrating clear-cut clinical utility and are, therefore, non-covered Late reactions occurring with allergenic extracts are of unclear clinical significance and are, therefore, non-covered Intradermal testing for food allergens Food allergen testing for patients who present with respiratory symptoms other than wheezing and asthma Food allergen testing for patients who present with gastrointestinal symptoms suggestive of food intolerance Skin endpoint testing Allergy testing for antigens for which no clinical efficacy is documented in peer-reviewed literature. Such antigens include but are not limited to the following: Grain mill dust (pollen grains of cereals/related crops are large; they do not become airborne) Tobacco smoke (no component has ever been shown to be a respiratory allergen) Orris root (almost never used in cosmetics these days; test adds nothing to evaluation) Dandelion (non-allergenic; no pollen produced) Marigold (non-allergenic; no airborne pollen produced) Honeysuckle (non-allergenic; non-significant airborne pollen produced) Allergy testing for certain antigens is covered only when performed on patients whose environment provides the reasonable probability of their exposure to antigens tested. Such antigens include, but are not limited to the following: Tobacco leaf for tobacco workers Pyrethrum for florists (non-allergenic; found in some insecticides; cross-reacts strongly with ragweed) Golden rod for florists (pollen not carried by wind) Soybean dust for workers in food processing plants Wool for patients exposed to sheep or unprocessed wool (processed wool is non-allergenic)